WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

WEST PHARMACEUTICAL SERVICES INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026

$383.91−0.11 (-0.03%)

Close on Oct 19, 2026

Market cap: $27.37B
P/E (TTM): 49.2
Dividend yield: 0.22%

WEST PHARMACEUTICAL SERVICES INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	3,074	2,893	2,950	2,887	2,832	2,147	1,840	1,717	1,599	1,509	1,400	1,421	1,368	1,266	1,192	1,105	1,056	1,051
Cost of Revenue	1,970	1,895	1,821	1,751	1,656	1,379	1,234	1,172	1,086	1,008	944	974	934	879	853	787	752	749
Gross Profit	1,104	999	1,129	1,136	1,176	768	606	545	513	501	456	448	435	388	339	318	304	303
Research & Development	74	69	68	59	53	47	39	40	39	37	34	37	38	33	29	24	20	19
Selling, General & Admin	394	339	353	317	363	302	273	263	246	240	233	229	235	218	191	188	178	159
Operating Income	585	570	676	734	752	407	297	240	226	195	129	182	162	135	110	91	98	124
Interest Expense	0.50	3.00	9.00	7.90	8.20	8.20	8.50	8.40	7.80	8.10	14	17	17	17	18	17	15	16
Income from Equity Investments	14	15	18	21	20	17	8.90	7.60	9.20	8.20	5.80	5.30	5.40	4.80	6.30	4.40	3.00	0.80
Other Non-Operating Income	-1.00	-1.00	3.00	-51	-3.40	-5.60	-4.80	0.40	3.10	1.60	–	–	–	–	4.20	-0.10	-0.20	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	26	–	–	–	2.10	5.30	–	–	–
Asset Impairment Charges	12	7.30	9.60	6.20	5.60	0	0.30	2.20	0	17	0	0	0	6.20	0	4.40	5.80	0
Gain (Loss) on Investments	–	–	-4.30	-3.50	0.30	-2.50	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	0	-12	0	0	-7.70	-0.80	1.10	-1.60	-0.70	-0.40	-0.30	-0.40	-1.70	0.20	-0.70	-0.90	0
Pretax Income	601	586	698	680	749	401	292	241	222	190	116	169	147	109	93	75	83	110
Income Tax Expense	122	108	122	115	107	73	59	41	81	54	26	47	40	33	24	14	14	24
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	242	207	151	144	96	127	112	81	76	65	73	87
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0.60
Net Income	494	493	593	586	662	346	242	207	–	–	–	–	–	–	–	65	73	86
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	127	112	83	80	70	77	–
EPS (Basic)(per share)	6.83	6.75	7.98	7.87	8.89	4.68	3.27	2.80	2.04	1.96	1.33	1.79	1.61	1.19	1.12	0.98	1.11	1.33
EPS (Diluted)(per share)	6.79	6.69	7.88	7.73	8.67	4.57	3.21	2.74	1.99	1.91	1.30	1.75	1.57	1.15	1.08	0.95	1.06	1.25
Shares Outstanding (Basic, Weighted)(shares)	72	73	74	74	74	74	74	74	74	73	72	71	70	68	67	67	66	65
Shares Outstanding (Diluted, Weighted)(shares)	73	74	75	76	76	76	75	75	76	75	74	73	71	72	74	73	73	72
Dividend per Share(per share)	0.86	0.82	0.78	0.74	0.70	0.66	0.62	0.58	0.54	0.50	0.46	0.41	0.39	0.37	0.35	0.33	0.31	0.29
EBITDA	756	725	813	855	875	516	400	345	323	286	219	272	248	212	185	164	166	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 36.8%
Operating margin: 20.5%
Net margin: 17.0%
Return on equity, FY2025: 16.9%

Financial strength

Current ratio: 2.82
Debt to equity: 0.07
Debt to assets: 5.0%
Cash to current liabilities: 68.0%

Valuation

P/E ratio: 49.2
Price to sales: 8.23
Price to book: 9.15
Dividend yield: 0.22%